How much do we know about schizophrenia and how well do we know it? Evidence from the Schizophrenia Library

Psychological Medicine

Volumn 44, Issue 16, 2014, Pages 3387-3405

  Matheson, S L ^a,b   Shepherd, A M ^a,b   Carr, V J ^a,b  

^a SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Biological aetiology; clinical phenomenology; cognition; epidemiology; intervention efficacy; risk factors

Indexed keywords

HUMAN; PATHOPHYSIOLOGY; PSYCHOLOGY; RISK FACTOR; SCHIZOPHRENIA;

HUMANS; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84908545956     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291714000166     Document Type: Article

References (225)

1. Achim AM, Lepage M (2005). Episodic memory-related activation in schizophrenia: meta-analysis. British Journal of Psychiatry 187, 500-509.
2. Achim AM, Maziade M, Raymond E, Olivier D, Merette C, Roy M (2011). How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophrenia Bulletin 37, 811-821.
3. Adams CE, Awad G, Rathbone J, Thornley B (2007). Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD000284. doi:10.1002/14651858.CD000284.pub2.
4. Adriano F, Caltagirone C, Spalletta G (2012). Hippocampal volume reduction in first-episode and chronic schizophrenia: a review and meta-analysis. Neuroscientist 18, 180-200.
5. Adriano F, Spoletini I, Caltagirone C, Spalletta G (2010). Updated meta-analyses reveal thalamus volume reduction in patients with first-episode and chronic schizophrenia. Schizophrenia Research 123, 1-4.
6. Aleman A, Agrawal N, Morgan KD, David AS (2006). Insight in psychosis and neuropsychological function: meta-analysis. British Journal of Psychiatry 189, 204-212.
7. Aleman A, Sommer IE, Kahn RS (2007). Efficacy of slow repetitive transcranial magnetic stimulation in the treatment of resistant auditory hallucinations in schizophrenia: a meta-analysis. Journal of Clinical Psychiatry 68, 416-421.
8. Allen NC, Bagade S, McQueen MB, Ioannidis JPA, Kavvoura FK, Khoury MJ, Tanzi RE, Bertram L (2008). Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nature Genetics 40, 827-834.
9. Alvarez-Jimenez M, Parker AG, Hetrick SE, McGorry PD, Gleeson JF (2011). Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. Schizophrenia Bulletin 37, 619-630.
10. Alvarez-Jimenez M, Priede A, Hetrick SE, Bendall S, Killackey E, Parker AG, McGorry PD, Gleeson JF (2012). Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophrenia Research 139, 116-128.
11. Anderson KK, Fuhrer R, Malla AK (2010). The pathways to mental health care of first-episode psychosis patients: a systematic review. Psychological Medicine 40, 1585-1597.
12. Anticevic A, Van Snellenberg JX, Cohen RE, Repovs G, Dowd EC, Barch DM (2012). Amygdala recruitment in schizophrenia in response to aversive emotional material: a meta-analysis of neuroimaging studies. Schizophrenia Bulletin 38, 608-621.
13. Arias I, Sorlozano A, Villegas E, de Dios Luna J, McKenney K, Cervilla J, Gutierrez B, Gutierrez J (2011). Infectious agents associated with schizophrenia: a meta-analysis. Schizophrenia Research 136, 128-136.
14. Arnone D, McIntosh AM, Tan GM, Ebmeier KP, Tan GMY (2008). Meta-analysis of magnetic resonance imaging studies of the corpus callosum in schizophrenia. Schizophrenia Research 101, 124-132.
15. Baiano M, David A, Versace A, Churchill R, Balestrieri M, Brambilla P (2007). Anterior cingulate volumes in schizophrenia: a systematic review and a meta-analysis of MRI studies. Schizophrenia Research 93, 1-12.
16. Beauchamp G, Gagnon A (2004). Influence of diagnostic classification on gender ratio in schizophrenia - a meta-analysis of youths hospitalized for psychosis. Social Psychiatry and Psychiatric Epidemiology 39, 1017-1022.
17. Begemann MJH, Dekker CF, van Lunenburg M, Sommer IE (2012). Estrogen augmentation in schizophrenia: a quantitative review of current evidence. Schizophrenia Research 141, 179-184.
18. Belgamwar RB, El-Sayeh HGG (2011). Aripiprazole versus placebo for schizophrenia. Cochrane Database of Systematic Reviews, Issue 8. Art. No.: CD006622. doi:10.1002/14651858. CD006622.pub2.
19. Berger GE, Wood SJ, Pantelis C, Velakoulis D, Wellard RM, McGorry PD (2002). Implications of lipid biology for the pathogenesis of schizophrenia. Australian and New Zealand Journal of Psychiatry 36, 355-366.
20. Bird V, Premkumar P, Kendall T, Whittington C, Mitchell J, Kuipers E (2010). Early intervention services, cognitive-behavioural therapy and family intervention in early psychosis: systematic review. British Journal of Psychiatry 197, 350-356.
21. Bokat CE, Goldberg TE (2003). Letter and category fluency in schizophrenic patients: a meta-analysis. Schizophrenia Research 64, 73-78.
22. Boonstra N, Klaassen R, Sytema S, Marshall M, De Haan L, Wunderink L, Wiersma D (2012). Duration of untreated psychosis and negative symptoms - a systematic review and meta-analysis of individual patient data. Schizophrenia Research 142, 12-19.
23. Bora E, Fornito A, Radua J, Walterfang M, Seal M, Wood SJ, Yücel M, Velakoulis D, Pantelis C (2011). Neuroanatomical abnormalities in schizophrenia: a multimodal voxelwise meta-analysis and meta-regression analysis. Schizophrenia Research 127, 46-57.
24. Bora E, Pantelis C (2013). Theory of mind impairments in first-episode psychosis, individuals at ultra-high risk for psychosis and in first-degree relatives of schizophrenia: systematic review and meta-analysis. Schizophrenia Research 144, 31-36.
25. Bora E, Yucel M, Pantelis C (2009a). Theory of mind impairment in schizophrenia: meta-analysis. Schizophrenia Research 109, 1-9.
26. Bora E, Yucel M, Pantelis C (2009b). Cognitive functioning in schizophrenia, schizoaffective disorder and affective psychoses: meta-analytic study. British Journal of Psychiatry 195, 475-482.
27. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR (2009). Introduction to Meta-Analysis. John Wiley and Sons: Chichester.
28. Bourque F, van der Ven E, Malla A (2011). A meta-analysis of the risk for psychotic disorders among first- and second-generation immigrants. Psychological Medicine 41, 897-910.
29. Bradley AJ, Dinan TG (2010). A systematic review of hypothalamic-pituitary-adrenal axis function in schizophrenia: implications for mortality. Journal of Psychopharmacology 24, 91-118.
30. Bramon E, McDonald C, Croft RJ, Landau S, Filbey F, Gruzelier JH, Sham PC, Frangou S, Murray RM (2005). Is the P300 wave an endophenotype for schizophrenia? A meta-analysis and a family study. Neuroimage 27, 960-968.
31. Bramon E, Rabe-Hesketh S, Sham P, Murray RM, Frangou S (2004). Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophrenia Research 70, 315-329.
32. Brugger S, Davis JM, Leucht S, Stone JM (2011). Proton magnetic resonance spectroscopy and illness stage in schizophreniaa systematic review and meta-analysis. Biological Psychiatry 69, 495-503.
33. Button KS, Ioannidis JPA, Mokrysz C, Nosek BA, Flint J, Robinson ESJ, Munafò MR (2013). Power failure: why small sample size undermines the reliability of neuroscience. Nature Reviews Neuroscience 14, 365-378.
34. Calkins ME, Iacono WG, Ones DS (2008). Eye movement dysfunction in first-degree relatives of patients with schizophrenia: a meta-analytic evaluation of candidate endophenotypes. Brain and Cognition 68, 436-461.
35. Cannon M, Jones PB, Murray RM (2002). Obstetric complications and schizophrenia: historical and meta-analytic review. American Journal of Psychiatry 159, 1080-1092.
36. Cantor-Graae E, Selten JP (2005). Schizophrenia and migration: a meta-analysis and review. American Journal of Psychiatry 162, 12-24.
37. Catts VS, Catts SV, O'Toole BI, Frost AD, Frost ADJ (2008). Cancer incidence in patients with schizophrenia and their first-degree relatives - a meta-analysis. Acta Psychiatrica Scandinavica 117, 323-336.
38. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B (2001). Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. American Journal of Psychiatry 158, 518-526.
39. Chan RCK, Di X, McAlonan GM, Gong QY (2011). Brain anatomical abnormalities in high-risk individuals, first-episode, and chronic schizophrenia: an activation likelihood estimation meta-analysis of illness progression. Schizophrenia Bulletin 37, 177-188.
40. Chan RCK, Li H, Cheung EFC, Gong Q-Y (2010a). Impaired facial emotion perception in schizophrenia: a meta-analysis. Psychiatry Research 178, 381-390.
41. Chan RCK, Xu T, Heinrichs RW, Yu Y, Gong QY (2010b). Neurological soft signs in non-psychotic first-degree relatives of patients with schizophrenia: a systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews 34, 889-896.
42. Chan RCK, Xu T, Heinrichs RW, Yu Y, Wang Y (2010c). Neurological soft signs in schizophrenia: a meta-analysis. Schizophrenia Bulletin 36, 1089-1104.
43. Chong TW, Castle DJ (2004). Layer upon layer: thermoregulation in schizophrenia. Schizophrenia Research 69, 149-157.
44. Chouinard S, Poulin J, Stip E, Godbout R (2004). Sleep in untreated patients with schizophrenia: a meta-analysis. Schizophrenia Bulletin 30, 957-967.
45. Chuma J, Mahadun P (2011). Predicting the development of schizophrenia in high-risk populations: systematic review of the predictive validity of prodromal criteria. British Journal of Psychiatry 199, 361-366.
46. Cochrane Collaboration (2008). Cochrane Handbook for Systematic Reviews of Interventions. John Wiley and Sons: Chichester.
47. Cohen AS, Brown LA, Auster TL (2012). Olfaction, "olfiction," and the schizophrenia-spectrum: an updated meta-analysis on identification and acuity. Schizophrenia Research 135, 152-157.
48. Cohen AS, Minor KS (2010). Emotional experience in patients with schizophrenia revisited: meta-analysis of laboratory studies. Schizophrenia Bulletin 36, 143-150.
49. Cohen J (1988). Statistical Power Analysis for the Behavioral Sciences, 2nd edn. Erlbaum: Hillsdale, NJ.
50. Copeland LA, Zeber JE, Pugh MJ, Mortensen EM, Restrepo MI, Lawrence VA (2008). Postoperative complications in the seriously mentally ill: a systematic review of the literature. Annals of Surgery 248, 31-38.
51. Crossley NA, Constante M, McGuire P, Power P (2010). Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. British Journal of Psychiatry 196, 434-439.
52. Crowther R, Marshall M, Bond G, Huxley P (2001). Vocational rehabilitation for people with severe mental illness. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD003080. doi:10.1002/14651858.CD003080.
53. de Gracia Dominguez M, Viechtbauer W, Simons CJ, van Os J, Krabbendam L (2009). Are psychotic psychopathology and neurocognition orthogonal? A systematic review of their associations. Psychological Bulletin 135, 157-171.
54. de Leon J, Diaz FJ (2005). A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophrenia Research 76, 135-157.
55. de Wilde OM, Bour LJ, Dingemans PM, Koelman JH, Linszen DH, Koelman JHTM (2007). A meta-analysis of P50 studies in patients with schizophrenia and relatives: differences in methodology between research groups. Schizophrenia Research 97, 137-151.
56. Demeulemeester M, Amad A, Bubrovszky M, Pins D, Thomas P, Jardri R (2012). What is the real effect of 1-Hz repetitive transcranial magnetic stimulation on hallucinations? Controlling for publication bias in neuromodulation trials. Biological Psychiatry 71, e15-e16.
57. Dibben CR, Rice C, Laws K, McKenna PJ (2009). Is executive impairment associated with schizophrenic syndromes? A meta-analysis. Psychological Medicine 39, 381-392.
58. Dickinson D, Ramsey ME, Gold JM (2007). Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Archives of General Psychiatry 64, 532-542.
59. Dickson H, Laurens KR, Cullen AE, Hodgins S (2012). Meta-analyses of cognitive and motor function in youth aged 16 years and younger who subsequently develop schizophrenia. Psychological Medicine 42, 743-755.
60. Dieterich M, Irving CB, Park B, Marshall M (2010). Intensive case management for severe mental illness. Cochrane Database of Systematic Reviews, Issue 10. Art. No.: CD007906. doi:10.1002/14651858.CD007906.pub2.
61. Dlabac-de Lange JJ, Knegtering R, Aleman A (2010). Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: review and meta-analysis. Journal of Clinical Psychiatry 71, 411-418.
62. Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S (2005). Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD001359. doi:10.1002/14651858. CD001359.pub2.
63. Eack SM, Newhill CE (2007). Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis. Schizophrenia Bulletin 33, 1225-1237.
64. Ellison-Wright I, Bullmore E (2009). Meta-analysis of diffusion tensor imaging studies in schizophrenia. Schizophrenia Research 108, 3-10.
65. Esterberg M, Trotmana HD, Holtzmana C, Compton MT, Walker EF (2010). The impact of a family history of psychosis on age-at-onset and positive and negative symptoms of schizophrenia: a meta-analysis. Schizophrenia Research 120, 121-130.
66. Farooq S, Large M, Nielssen O, Waheed W (2009). The relationship between the duration of untreated psychosis and outcome in low- and-middle income countries: a systematic review and meta analysis. Schizophrenia Research 109, 15-23.
67. Fazel S, Gulati G, Linsell L, Geddes JR, Grann M (2009). Schizophrenia and violence: systematic review and meta-analysis. PLoS Medicine 6, 120.
68. Fazel S, Khosla V, Doll H, Geddes J (2008). The prevalence of mental disorders among the homeless in western countries: systematic review and meta-regression analysis. PLoS Medicine 5, e225.
69. Fazel S, Seewald K (2012). Severe mental illness in 33 588 prisoners worldwide: systematic review and meta-regression analysis. British Journal of Psychiatry 200, 364-373.
70. Fekadu A, Shibre T, Cleare AJ (2010). Toxoplasmosis as a cause for behaviour disorders - overview of evidence and mechanisms. Folia Parasitologica 57, 105-113.
71. Fenton WS, Hibbeln J, Knable M (2000). Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biological Psychiatry 47, 8-21.
72. Fett AK, Viechtbauer W, Dominguez MD, Penn DL, van Os J, Krabbendam L (2011). The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neuroscience and Biobehavioral Reviews 35, 573-588.
73. Folsom D, Jeste DV (2002). Schizophrenia in homeless persons: a systematic review of the literature. Acta Psychiatrica Scandinavica 105, 404-413.
74. Forbes NF, Carrick LA, McIntosh AM, Lawrie SM (2009). Working memory in schizophrenia: a meta-analysis. Psychological Medicine 39, 889-905.
75. Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, Valmaggia L, Barale F, Caverzasi E, McGuire P (2012a). Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Archives of General Psychiatry 69, 220-229.
76. Fusar-Poli P, Deste G, Smieskova R, Barlati S, Yung AR, Howes O, Stieglitz RD, Vita A, McGuire P, Borgwardt S (2012b). Cognitive functioning in prodromal psychosis: a meta-analysis. Archives of General Psychiatry 69, 562-571.
77. Fusar-Poli P, Meyer-Lindenberg A (2013a). Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [18F/11C]-DOPA PET studies. Schizophrenia Bulletin 39, 33-42.
78. Fusar-Poli P, Meyer-Lindenberg A (2013b). Striatal presynaptic dopamine in schizophrenia, part I: meta-analysis of dopamine active transporter (DAT) density. Schizophrenia Bulletin 39, 22-32.
79. Fusar-Poli P, Smieskova R, Kempton MJ, Ho BC, Andreasen NC, Borgwardt S (2013). Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neuroscience and Biobehavioral Reviews 37, 1680-1691.
80. Galderisi S, Mucci A, Volpe U, Boutros N (2009). Evidence-based medicine and electrophysiology in schizophrenia. Clinical EEG and Neuroscience 40, 62-77.
81. Goghari VM (2011). Executive functioning-related brain abnormalities associated with the genetic liability for schizophrenia: an activation likelihood estimation meta-analysis. Psychological Medicine 41, 1239-1252.
82. Gold C, Solli HP, Kruger V, Lie SA (2009). Dose-response relationship in music therapy for people with serious mental disorders: systematic review and meta-analysis. Clinical Psychology Review 29, 193-207.
83. Golembo-Smith S, Walder DJ, Daly MP, Mittal VA, Kline E, Reeves G, Schiffman J (2012). The presentation of dermatoglyphic abnormalities in schizophrenia: a meta-analytic review. Schizophrenia Research 142, 1-11.
84. GRADE Working Group (2004). Grading quality of evidence and strength of recommendations. BMJ (Clinical Research Edition) 328, 1490.
85. Green MJ, Matheson SL, Shepherd A, Weickert CS, Carr VJ (2011). Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Molecular Psychiatry 16, 960-972.
86. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, deBeer H, Jaeschke R, Rind D, Meerpohl J, Dahm P, Schünemann HJ (2011a). GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 64, 383-394.
87. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, Alonso-Coello P, Glasziou O, Jaeschke R, Akl EA, Norris S, Vist G, Dahm P, Shukla VK, Higgins J, Falck-Ytter Y, Schünemann HJ; GRADE Working Group (2011b). GRADE guidelines: 7. Rating the quality of evidence - inconsistency. Journal of Clinical Epidemiology 64, 1294-1302.
88. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, Devereaux PJ, Montori VM, Freyschuss B, Vist G, Jaeschke R, Williams JWJ, Murad MH, Sinclair D, Falck-Ytter Y, Meerpohl J, Whittington C, Thorlund K, Andrews J, Schünemann HJ (2011c). GRADE guidelines: 6. Rating the quality of evidence - imprecision. Journal of Clinical Epidemiology 64, 1283-1293.
89. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, Alonso-Coello P, Falck-Ytter Y, Jaeschke R, Vist G, Akl EA, Post PN, Norris S, Meerpohl J, Shukla VK, Nasser M, Schünemann HJ; GRADE Working Group (2011d). GRADE guidelines: 8. Rating the quality of evidence - indirectness. Journal of Clinical Epidemiology 64, 1303-1310.
90. Haijma SV, Van Haren N, Cahn W, Koolschijn PCMP, Hulshoff Pol HE, Kahn RS (2013). Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects. Schizophrenia Bulletin 39, 1129-1138.
91. Harrison PJ, Freemantle N, Geddes JR (2003). Meta-analysis of brain weight in schizophrenia. Schizophrenia Research 64, 25-34.
92. Howes O, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, Kapur S (2012). The nature of dopamine dysfunction in schizophrenia and what this means for treatment: meta-analysis of imaging studies. Archives of General Psychiatry 69, 776-786.
93. Ioannidis JPA (2005). Why most published research findings are false. PLoS Medicine 2, e124.
94. Irani F, Seligman S, Kamath V, Kohler C, Gur RC (2012). A meta-analysis of emotion perception and functional outcomes in schizophrenia. Schizophrenia Research 137, 203-211.
95. Irving CB, Adams CE, Lawrie SM (2006). Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews, Issue 4. Art. No.: CD003082. doi:10.1002/14651858. CD003082.pub2.
96. Jardri R, Pouchet A, Pins D, Thomas P (2011). Cortical activations during auditory verbal hallucinations in schizophrenia: a coordinate-based meta-analysis. American Journal of Psychiatry 168, 73-81.
97. Johnson-Selfridge M, Zalewski C (2001). Moderator variables of executive functioning in schizophrenia: meta-analytic findings. Schizophrenia Bulletin 27, 305-316.
98. Jones C, Hacker D, Cormac I, Meaden A, Irving CB (2012). Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia. Cochrane Database of Systematic Reviews, Issue 4. Art. No.: CD008712. doi:10.1002/14651858. CD008712.pub2.
99. Kempton M, Stahl D, Williams SCR, DeLisi LE (2010). Progressive lateral ventricular enlargement in schizophrenia: a meta-analysis of longitudinal MRI studies. Schizophrenia Research 120, 54-62.
100. Keshavan MS, Tandon R, Boutros NN, Nasrallah HA (2008). Schizophrenia, part 3 - Just the Facts. What we know in 2008: neurobiology. Schizophrenia Research 106, 89-107.
101. Khandaker GM, Barnett JH, White IR, Jones PB (2011). A quantitative meta-analysis of population-based studies of premorbid intelligence and schizophrenia. Schizophrenia Research 132, 220-227.
102. Khandaker GM, Zimbron J, Dalman C, Lewis G, Jones PB (2012). Childhood infection and adult schizophrenia: a meta-analysis of population-based studies. Schizophrenia Research 139, 161-168.
103. Khandaker GM, Zimbron J, Lewis G, Jones PB (2013). Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population based studies. Psychological Medicine 43, 239-257.
104. Kinney DK, Teixeira P, Hsu D, Napoleon SC, Crowley DJ, Miller A, Hyman W, Huang E (2009). Relation of schizophrenia prevalence to latitude, climate, fish consumption, infant mortality, and skin color: a role for prenatal vitamin D deficiency and infections? Schizophrenia Bulletin 35, 582-595.
105. Kirkbride JB, Errazuriz A, Croudace TJ, Morgan C, Jackson D, Boydell J, Murray RM, Jones PB (2012). Incidence of schizophrenia and other psychoses in England, 1950-2009: a systematic review and meta-analyses. PLOS ONE 7, e31660.
106. Knowles EEM, David AS, Reichenberg A (2010). Processing speed deficits in schizophrenia: reexamining the evidence. American Journal of Psychiatry 167, 828-835.
107. Kohler C, Walker J, Martin E, Healey K, Moberg P (2010). Facial emotion perception in schizophrenia: a meta-analytic review. Schizophrenia Bulletin 36, 1009-1019.
108. Kompus K, Westerhausen R, Hugdahl K (2011). The "paradoxical" engagement of the primary auditory cortex in patients with auditory verbal hallucinations: a meta-analysis of functional neuroimaging studies. Neuropsychologia 49, 3361-3369.
109. Koskinen J, Lohonen J, Koponen H, Isohanni M, Miettunen J (2010). Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophrenia Bulletin 36, 1115-1130.
110. Krabbendam L, Arts B, van Os J, Aleman A (2005). Cognitive functioning in patients with schizophrenia and bipolar disorder: a quantitative review. Schizophrenia Research 80, 137-149.
111. Kraguljac NV, Reid M, White D, Jones R, den Hollander J, Lowman D, Lahti AC (2012). Neurometabolites in schizophrenia and bipolar disorder - a systematic review and meta-analysis. Psychiatry Research 203, 111-125.
112. Kuhn S, Gallinat J (2012). Quantitative meta-analysis on state and trait aspects of auditory verbal hallucinations in schizophrenia. Schizophrenia Bulletin 38, 779-786.
113. Kurtz MM, Mueser KT (2008). A meta-analysis of controlled research on social skills training for schizophrenia. Journal of Consulting and Clinical Psychology 76, 491-504.
114. Kurtz MM, Richardson CL (2012). Social cognitive training for schizophrenia: a meta-analytic investigation of controlled research. Schizophrenia Bulletin 38, 1092-1104.
115. Kuswanto CN, Teh I, Lee TS, Sim K (2012). Diffusion tensor imaging findings of white matter changes in first episode schizophrenia: a systematic review. Clinical Psychopharmacology and Neuroscience 10, 13-24.
116. Large M, Nielssen O (2008). Evidence for a relationship between the duration of untreated psychosis and the proportion of psychotic homicides prior to treatment. Social Psychiatry and Psychiatric Epidemiology 43, 37-44.
117. Large M, Sharma S, Compton MT, Slade T, Nielssen O (2011a). Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Archives of General Psychiatry 68, 555-561.
118. Large M, Smith G, Sharma S, Nielssen O, Singh SP (2011b). Systematic review and meta-analysis of the clinical factors associated with the suicide of psychiatric in-patients. Acta Psychiatrica Scandinavica 124, 18-19.
119. Large MM, Nielssen O, Ryan CJ, Hayes R (2008). Mental health laws that require dangerousness for involuntary admission may delay the initial treatment of schizophrenia. Social Psychiatry and Psychiatric Epidemiology 43, 251-256.
120. Leucht S, Kissling W, McGrath J (2007a). Lithium for schizophrenia. Cochrane Database of Systematic Reviews, Issue 3. Art. No.: CD003834. doi:10.1002/14651858. CD003834.
121. Leucht S, Burkard T, Henderson J, Maj M, Sartorius N (2007b). Physical illness and schizophrenia: a review of the literature. Acta Psychiatrica Scandinavica 116, 317-333.
122. Leucht S, Lasser R (2006). The concepts of remission and recovery in schizophrenia. Pharmacopsychiatry 39, 161-170.
123. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM (2012a). Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews, Issue 5. Art. No.: CD008016. doi:10.1002/14651858.CD008016.pub2.
124. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM (2012b). Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379, 2063-2071.
125. Li H, Chan R, McAlonan G, Gong Q (2010). Facial emotion processing in schizophrenia: a meta-analysis of functional neuroimaging data. Schizophrenia Bulletin 36, 1029-1039.
126. Livingston JD, Boyd JE (2010). Correlates and consequences of internalized stigma for people living with mental illness: a systematic review and meta-analysis. Social Science and Medicine 71, 2150-2161.
127. Llerena K, Strauss GP, Cohen AS (2012). Looking at the other side of the coin: a meta-analysis of self-reported emotional arousal in people with schizophrenia. Schizophrenia Research 142, 65-70.
128. MacDonald AW, Schulz SC (2009). What we know: findings that every theory of schizophrenia should explain. Schizophrenia Bulletin 35, 493-508.
129. MacDonald AW 3rd, Thermenos HW, Barch DM, Seidman LJ (2009). Imaging genetic liability to schizophrenia: systematic review of FMRI studies of patients' nonpsychotic relatives. Schizophrenia Bulletin 35, 1142-1162.
130. Maniglio R (2009). Severe mental illness and criminal victimization: a systematic review. Acta Psychiatrica Scandinavica 119, 180-191.
131. Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T (2005). Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Archives of General Psychiatry 62, 975-983.
132. Marsman A, Van Den Heuvel MP, Klomp DWJ, Kahn RS, Luijten PR, Hulshoff Pol HE (2013). Glutamate in schizophrenia: a focused review and meta-analysis of 1H-MRS studies. Schizophrenia Bulletin 39, 120-129.
133. Matheson SL, Shepherd AM, Pinchbeck RM, Laurens KR, Carr VJ (2012). Childhood adversity in schizophrenia: a systematic meta-analysis. Psychological Medicine 43, 225-238.
134. McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D (2004). A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Medicine 2, 13.
135. McGurk SR, Twamley EW, Sitzer DI, McHugo GJ, Mueser KT (2007). A meta-analysis of cognitive remediation in schizophrenia. American Journal of Psychiatry 164, 1791-1802.
136. Menezes NM, Arenovich T, Zipursky RB (2006). A systematic review of longitudinal outcome studies of first-episode psychosis. Psychological Medicine 36, 1349-1362.
137. Mesholam-Gately RI, Giuliano AJ, Goff KP, Faraone SV, Seidman LJ (2009). Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology 23, 315-336.
138. Meyer JM, Stahl SM (2009). The metabolic syndrome and schizophrenia. Acta Psychiatrica Scandinavica 119, 4-14.
139. Miller B, Messias E, Miettunen J, Alaraisanen A, Jarvelin MR, Koponen H, Rasanen P, Isohanni M, Kirkpatrick B (2011). Meta-analysis of paternal age and schizophrenia risk in male versus female offspring. Schizophrenia Bulletin 37, 1039-1047.
140. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B (2011). Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biological Psychiatry 70, 663-671.
141. Mintz AR, Dobson KS, Romney DM (2003). Insight in schizophrenia: a meta-analysis. Schizophrenia Research 61, 75-88.
142. Minzenberg MJ, Laird AR, Thelen S, Carter CS, Glahn DC (2009). Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Archives of General Psychiatry 66, 811-822.
143. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (Clinical Research Ed) 151, 264-269.
144. Molloy C, Conroy RM, Cotter DR, Cannon M (2011). Is traumatic brain injury a risk factor for schizophrenia? A meta-analysis of case-controlled population-based studies. Schizophrenia Bulletin 37, 1104-1110.
145. Moncrieff J (2003). Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination. British Journal of Psychiatry 183, 161-166.
146. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370, 319-328.
147. Mössler K, Chen X, Heldal TO, Gold C (2011). Music therapy for people with schizophrenia and schizophrenia-like disorders. Cochrane Database of Systematic Reviews, Issue 12. Art. No.: CD004025. doi:10.1002/ 14651858.CD004025.pub3.
148. Mota NE, Lima MS, Soares BG (2002). Amisulpride for schizophrenia. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD001357. doi:10.1002/14651858. CD001357.
149. Murphy S, Irving CB, Adams CE, Driver R (2012). Crisis intervention for people with severe mental illnesses. Cochrane Database of Systematic Reviews, Issue 5. Art. No.: CD001087. doi:10.1002/14651858.CD001087.pub4.
150. Newton-Howes G, Tyrer P, North B, Yang M (2008). The prevalence of personality disorder in schizophrenia and psychotic disorders: systematic review of rates and explanatory modelling. Psychological Medicine 38, 1075-1082.
151. Nieuwenstein MR, Aleman A, de Haan EH (2001). Relationship between symptom dimensions and neurocognitive functioning in schizophrenia: a meta-analysis of WCST and CPT studies. Wisconsin Card Sorting Test. Continuous performance test. Journal of Psychiatric Research 35, 119-125.
152. Nussbaum AM, Stroup TS (2008). Oral paliperidone for schizophrenia. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD006369. doi:10.1002/14651858. CD006369.pub2.
153. O'Driscoll GA, Callahan BL (2008). Smooth pursuit in schizophrenia: a meta-analytic review of research since 1993. Brain and Cognition 68, 359-370.
154. Olabi B, Ellison-Wright I, McIntosh AM, Wood SJ, Bullmore E, Lawrie SM (2011). Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies. Biological Psychiatry 70, 88-96.
155. Osborn DP, Wright CA, Levy G, King MB, Deo R, Nazareth I (2008). Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: systematic review and metaanalysis. BMC Psychiatry 8, 84.
156. Oud MJ, Meyboom-De Jong B (2009). Somatic diseases in patients with schizophrenia in general practice: their prevalence and health care. BMC Family Practice 10, 32.
157. Palaniyappan L, Balain V, Liddle PF (2012). The neuroanatomy of psychotic diathesis: a meta-analytic review. Journal of Psychiatric Research 46, 1249-1256.
158. Palmer BA, Pankratz VS, Bostwick JM (2005). The lifetime risk of suicide in schizophrenia: a reexamination. Archives of General Psychiatry 62, 247-253.
159. Patel S, Mahon K, Wellington R, Zhang J, Chaplin W, Szeszko PR (2011). A meta-analysis of diffusion tensor imaging studies of the corpus callosum in schizophrenia. Schizophrenia Research 129, 149-155.
160. Pelletier M, Achim AM, Montoya A, Lal S, LepageM(2005). Cognitive and clinical moderators of recognition memory in schizophrenia: a meta-analysis. Schizophrenia Research 74, 233-252.
161. Pfammatter M, Junghan UM, Brenner HD (2006). Efficacy of psychological therapy in schizophrenia: conclusions from meta-analyses. Schizophrenia Bulletin 32, S64-S80.
162. Pharoah F, Mari J, Rathbone J, Wong W (2010). Family intervention for schizophrenia. Cochrane Database of Systematic Reviews, Issue 4. Art. No.: CD000088. doi:10.1002/ 14651858.CD000088.pub2.
163. Potvin S, Blanche P, Stip E (2009). Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: a meta-analysis. Schizophrenia Research 113, 181-188.
164. Potvin S, Marchand S (2008). Hypoalgesia in schizophrenia is independent of antipsychotic drugs: a systematic quantitative review of experimental studies. Pain 138, 70-78.
165. Potvin S, Sepehry AA, Stip E (2006). A meta-analysis of negative symptoms in dual diagnosis schizophrenia. Psychological Medicine 36, 431-440.
166. Preti A, Cella M (2010). Randomized-controlled trials in people at ultra high risk of psychosis: a review of treatment effectiveness. Schizophrenia Research 123, 30-36.
167. Ragland JD, Laird AR, Ranganath C, Blumenfeld RS, Gonzales SM, Glahn DC (2009). Prefrontal activation deficits during episodic memory in schizophrenia. American Journal of Psychiatry 166, 863-874.
168. Rajji TK, Ismail Z, Mulsant BH (2009). Age at onset and cognition in schizophrenia: meta-analysis. British Journal of Psychiatry 195, 286-293.
169. Rattehalli RD, Jayaram MB, Smith M (2010). Risperidone versus placebo for schizophrenia. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD006918. doi:10.1002/ 14651858.CD006918.pub2.
170. Read J, Haslam N, Sayce L, Davies E (2006). Prejudice and schizophrenia: a review of the 'mental illness is an illness like any other' approach. Acta Psychiatrica Scandinavica 114, 303-318.
171. Rietkerk T, Boks MP, Sommer IE, Liddle PF, Ophoff RA, Kahn RS, Boks MPM (2008). The genetics of symptom dimensions of schizophrenia: review and meta-analysis. Schizophrenia Research 102, 197-205.
172. Roder V, Mueller DR, Schmidt SJ (2011). Effectiveness of integrated psychological therapy (IPT) for schizophrenia patients: a research update. Schizophrenia Bulletin 37, S71-S79.
173. Rosenthal JA (1996). Qualitative descriptors of strength of association and effect size. Journal of Social Service Research 21, 37-58.
174. Rubio JM, Sanjuán J, Flórez-Salamanca L, Cuesta MJ (2012). Examining the course of hallucinatory experiences in children and adolescents: a systematic review. Schizophrenia Research 138, 248-254.
175. Saha S, Chant D, McGrath J (2007). A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Archives of General Psychiatry 64, 1123-1131.
176. Saha S, Chant D, Welham J, McGrath J (2005). A systematic review of the prevalence of schizophrenia. PLoS Medicine 2, e141.
177. Sarin F, Wallin L, Widerlov B (2011). Cognitive behavior therapy for schizophrenia: a meta-analytical review of randomized controlled trials. Nordic Journal of Psychiatry 65, 162-174.
178. Savla GN, Vella L, Armstrong CC, Penn DL, Twamley EW (2012). Deficits in domains of social cognition in schizophrenia: a meta-analysis of the empirical evidence. Schizophrenia Bulletin. Published online 4 September 2012. doi:10.1093/schbul/sbs1080.
179. Schmidt SJ, Mueller DR, Roder V (2011). Social cognition as a mediator variable between neurocognition and functional outcome in schizophrenia: empirical review and new results by structural equation modeling. Schizophrenia Bulletin 37, S41-S54.
180. Schroeter ML, Abdul-Khaliq H, Krebs M, Diefenbacher A, Blasig IE (2009). Neuron-specific enolase is unaltered whereas S100B is elevated in serum of patients with schizophrenia - original research and meta-analysis. Psychiatry Research 167, 66-72.
181. Schultz PW, Searleman A (2002). Rigidity of thought and behavior: 100 years of research. Genetic, Social, and General Psychology Monographs 128, 165-207.
182. Shepherd AM, Matheson SL, Laurens KR, Carr VJ, Green MJ (2012). Systematic meta-analysis of insula volume in schizophrenia. Biological Psychiatry 72, 775-784.
183. Singh SP, Singh V (2011). Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs 5, 859-885.
184. Singh V, Singh SP, Chan K (2010a). Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia. International Journal of Neuropsychopharmacology 13, 257-271.
185. Singh S, Singh V, Kar N, Chan K (2010b). Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. British Journal of Psychiatry 197, 174-179.
186. Sitskoorn MM, Aleman A, Ebisch SJ, Appels MC, Kahn RS (2004). Cognitive deficits in relatives of patients with schizophrenia: a meta-analysis. Schizophrenia Research 71, 285-295.
187. Slotema CW, Aleman A, Daskalakis ZJ, Sommer IE (2012). Meta-analysis of repetitive transcranial magnetic stimulation in the treatment of auditory verbal hallucinations: update and effects after one month. Schizophrenia Research 142, 40-45.
188. Snitz BE, Macdonald AW 3rd, Carter CS (2006). Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophrenia Bulletin 32, 179-194.
189. Sommer I, Ramsey N, Kahn R, Aleman A, Bouma A (2001). Handedness, language lateralisation and anatomical asymmetry in schizophrenia: meta-analysis. British Journal of Psychiatry 178, 344-351.
190. Sommer IE, de Witte L, Begemann M, Kahn RS (2012). Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. Journal of Clinical Psychiatry 73, 414-419.
191. Sprong M, Schothorst P, Vos E, Hox J, van Engeland H (2007). Theory of mind in schizophrenia: meta-analysis. British Journal of Psychiatry 191, 5-13.
192. Stefanopoulou E, Manoharan A, Landau S, Geddes JR, Goodwin G, Frangou S (2009). Cognitive functioning in patients with affective disorders and schizophrenia: a meta-analysis. International Review of Psychiatry 21, 336-356.
193. Su L, Cai Y, Wang L, Shi S (2012). Various effects of antipsychotics on P50 sensory gating in Chinese schizophrenia patients: a meta-analysis. Psychiatria Danubina 24, 44-50.
194. Sullivan PF, Kendler KS, Neale MC (2003). Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Archives of General Psychiatry 60, 1187-1192.
195. Szoke A, Schurhoff F, Mathieu F, Meary A, Ionescu S, Leboyer M (2005). Tests of executive functions in first-degree relatives of schizophrenic patients: a meta-analysis. Psychological Medicine 35, 771-782.
196. Tandon R, Keshavan MS, Nasrallah HA (2008a). Schizophrenia, part 1 - Just the Facts. What we know in 2008: an overview. Schizophrenia Research 100, 4-19.
197. Tandon R, Keshavan MS, Nasrallah HA (2008b). Schizophrenia, part 2 - Just the Facts. What we know in 2008. Epidemiology and etiology. Schizophrenia Research 102, 1-18.
198. Tandon R, Nasrallah HA, Keshavan MS (2009). Schizophrenia, part 4 - Just the Facts. Clinical features and conceptualization. Schizophrenia Research 110, 1-23.
199. Tandon R, Nasrallah HA, Keshavan MS (2010). Schizophrenia, 'Just the Facts': 5. Treatment and prevention. Past, present, and future. Schizophrenia Research 122, 1-23.
200. Tarbox SI, Pogue-Geile MF (2008). Development of social functioning in preschizophrenia children and adolescents: a systematic review. Psychological Bulletin 134, 561-583.
201. Taylor SF, Kang J, Brege IS, Tso IF, Hosanagar A, Johnson TD (2012). Meta-analysis of functional neuroimaging studies of emotion perception and experience in schizophrenia. Biological Psychiatry 71, 136-145.
202. Tharyan P, Adams CE (2005). Electroconvulsive therapy for schizophrenia. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD000076. doi:10.1002/14651858.CD000076.pub2.
203. Torrey EF, Bartko JJ, Yolken RH (2012). Toxoplasma gondii and other risk factors for schizophrenia: an update. Schizophrenia Bulletin 38, 642-647.
204. Trandafir A, Meary A, Schurhoff F, Leboyer M, Szoke A (2006). Memory tests in first-degree adult relatives of schizophrenic patients: a meta-analysis. Schizophrenia Research 81, 217-226.
205. Trzesniak C, de Oliveira IR, Kempton MJ, Galvão-de Almeida A, Chagas MHN, Ferrari MCF, Filho AS, Zuardi AW, Prado DA, Busatto GF, McGuire PK, Hallak JEC, Crippa JAS (2011a). Are cavum septum pellucidum abnormalities more common in schizophrenia spectrum disorders? A systematic review and meta-analysis. Schizophrenia Research 125, 1-12.
206. Trzesniak C, Kempton MJ, Busatto GF, de Oliveira IR, Galvao-de Almeida A, Kambeitz J, Ferrari MCF, Santos A, Chagas MHN, Zuardi AW, Hallak JEC, McGuire PK, Crippa JAS (2011b). Adhesio interthalamica alterations in schizophrenia spectrum disorders: a systematic review and meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry 35, 877-886.
207. Umbricht D, Krljes S (2005). Mismatch negativity in schizophrenia: a meta-analysis. Schizophrenia Research 76, 1-23.
208. van der Kemp WJM, Klomp DWJ, Kahn RS, Luijten PR, Hulshoff Pol HE (2012). A meta-analysis of the polyunsaturated fatty acid composition of erythrocyte membranes in schizophrenia. Schizophrenia Research 141, 153-161.
209. Van Snellenberg JX, Torres IJ, Thornton AE (2006). Functional neuroimaging of working memory in schizophrenia: task performance as a moderating variable. Neuropsychology 20, 497-510.
210. Vassos E, Pedersen CB, Murray RM, Collier DA, Lewis CM (2012). Meta-analysis of the association of urbanicity with schizophrenia. Schizophrenia Bulletin 38, 1118-1123.
211. Ventura J, Thames AD, Wood RC, Guzik LH, Hellman GS (2010). Disorganization and reality distortion in schizophrenia: a meta-analysis of the relationship between positive symptoms and neurocognitive deficits. Schizophrenia Research 121, 1-14.
212. Ventura J, Wood RC, Hellemann GS (2013). Symptom domains and neurocognitive functioning can help differentiate social cognitive processes in schizophrenia: a meta-analysis. Schizophrenia Bulletin 39, 102-111.
213. Wang K, Cheung EFC, Gong QY, Chan RCK (2011). Semantic processing disturbance in patients with schizophrenia: a meta-analysis of the N400 component. PLoS ONE 6, e25435.
214. Wang Y, Cui J, Chan RCK, Deng Y, Shi H, Hong X, Li Z, Yu X, Gong Q-Y, Shum D (2009). Meta-analysis of prospective memory in schizophrenia: nature, extent, and correlates. Schizophrenia Research 114, 64-70.
215. Waters F, Woodward T, Allen P, Aleman A, Sommer I (2012). Self-recognition deficits in schizophrenia patients with auditory hallucinations: a meta-analysis of the literature. Schizophrenia Bulletin 38, 741-750.
216. Weinberg SM, Jenkins EA, Marazita ML, Maher BS (2007). Minor physical anomalies in schizophrenia: a meta-analysis. Schizophrenia Research 89, 72-85.
217. Welham J, Isohanni M, Jones P, McGrath J (2009). The antecedents of schizophrenia: a review of birth cohort studies. Schizophrenia Bulletin 35, 603-623.
218. Whyte MC, McIntosh AM, Johnstone EC, Lawrie SM (2005). Declarative memory in unaffected adult relatives of patients with schizophrenia: a systematic review and meta-analysis. Schizophrenia Research 78, 13-26.
219. Woodberry KA, Giuliano AJ, Seidman LJ (2008). Premorbid IQ in schizophrenia: a meta-analytic review. American Journal of Psychiatry 165, 579-587.
220. Woodward ND, Purdon SE, Meltzer HY, Zald DH (2005). A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. International Journal of Neuropsychopharmacology 8, 457-472.
221. Wright IC, Rabe-Hesketh S, Woodruff PW, David AS, Murray RM, Bullmore ET (2000). Meta-analysis of regional brain volumes in schizophrenia. American Journal of Psychiatry 157, 16-25.
222. Xia J, Merinder LB, Belgamwar MR (2011). Psychoeducation for schizophrenia. [update of Cochrane Database Syst Rev. 2002;(2):CD002831].
223. Cochrane Database of Systematic Reviews, Issue 6. Art. No.: CD002831. doi:10.1002/14651858. CD002831.pub2.
224. Xu T, Chan RCK, Compton MT (2011). Minor physical anomalies in patients with schizophrenia, unaffected first-degree relatives, and healthy controls: a meta-analysis. PLoS ONE 6, e24129.
225. Yucel M, Bora E, Lubman DI, Solowij N, Brewer WJ, Cotton SM, Conus P, Takagi MJ, Fornito A, Wood SJ, McGorry PD, Pantelis C (2012). The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophrenia Bulletin 38, 316-330.